Nivalis Therapeutics, Inc. (ALPN) Downgraded by Zacks Investment Research to Hold
Nivalis Therapeutics, Inc. (NASDAQ:ALPN) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday.
According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “
Several other analysts have also issued reports on ALPN. ValuEngine upgraded shares of Nivalis Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 27th. Ladenburg Thalmann Financial Services assumed coverage on shares of Nivalis Therapeutics in a research report on Thursday, July 27th. They issued a “buy” rating and a $17.00 price target on the stock. Finally, Cowen and Company restated a “hold” rating on shares of Nivalis Therapeutics in a research report on Wednesday, April 19th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. Nivalis Therapeutics presently has an average rating of “Hold” and an average price target of $8.81.
Shares of Nivalis Therapeutics (NASDAQ:ALPN) traded down 4.34% during trading on Thursday, hitting $8.81. 36,013 shares of the stock traded hands. Nivalis Therapeutics has a one year low of $8.00 and a one year high of $37.40. The company’s market cap is $11.81 million. The firm has a 50 day moving average price of $9.32 and a 200-day moving average price of $9.83.
In other Nivalis Therapeutics news, insider Value Fund L. P. Biotechnology bought 17,806 shares of the firm’s stock in a transaction dated Tuesday, June 20th. The shares were acquired at an average cost of $2.25 per share, for a total transaction of $40,063.50. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Value Fund L. P. Biotechnology bought 78,858 shares of the firm’s stock in a transaction dated Friday, May 19th. The shares were acquired at an average price of $2.30 per share, for a total transaction of $181,373.40. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 288,964 shares of company stock worth $660,495. 3.00% of the stock is owned by company insiders.
Nivalis Therapeutics Company Profile
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.